GABA and brain abnormalities in schizophrenia

Psychiatry Research - Neuroimaging

Volumn 82, Issue 1, 1998, Pages 25-35

  Van Kammen, Daniel P ^a,b   Petty, Frederick ^c,d   Kelley, Mary E ^a   Kramer, Gerald L ^c   Barry, Ethan J ^a   Yao, Jeffrey K ^a,b   Gurklis, John A ^a,b   Peters, Jeffrey L ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c VA North Texas Health Care System   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Computed tomography; CSF; Plasma; Prefrontal sulcus; Ventricle brain ratio (VBR)

Indexed keywords

4 AMINOBUTYRIC ACID; HALOPERIDOL;

ADULT; ARTICLE; BLOOD LEVEL; BRAIN; BRAIN ATROPHY; BRAIN VENTRICLE; CEREBROSPINAL FLUID LEVEL; COMPUTER ASSISTED TOMOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCHIZOPHRENIA;

ADULT; ANALYSIS OF VARIANCE; ATROPHY; BRAIN; CEREBRAL VENTRICLES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; GAMMA-AMINOBUTYRIC ACID; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; PREFRONTAL CORTEX; SCHIZOPHRENIA; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0032502581     PISSN: 09254927     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0925-4927(98)00006-7     Document Type: Article

References (86)

1. Akbarian S., Kim J.J., Potkin S.G., Hagman J.O., Tafazzoli A., Bunney W.E. Jr., Jones E.G. Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics. Archives of General Psychiatry. 52:1995;258-266.
2. Alexander G.E., Crutcher M.D. Functional architecture of basal ganglia circuits: neural substrates of parallel processing. Trends in Neuroscience. 13:1990;266-271.
3. American Psychiatric Association, 1987. Diagnostic and Statistical Manual of Mental Disorders, 3rd ed. Revised. American Psychiatric Association, Washington, DC.
4. Andreasen N.C., Arndt S., Swayze V., Cizadio T., Flaum M., O'Leary D.S., Ehrhardt J.C., Yuh W.T.C. Thalamic abnormalities in schizophrenia visualized through magnetic resonance image averaging. Science. 266:1994;294-298.
5. Andreasen N.C., Flashman L., O'Leary D.S., Flaum M., Swayze V. Decreased frontal lobe size in schizophrenia measured with volumetric magnetic resonance (MR) imaging. Society of Neuroscience Abstracts. 20:1994;24.
6. Arnold S.E., Franz B.R., Gur R.C., Gur R.E., Shapiro R.M., Moberg P.J., Trojanowski J.Q. Decreased neuron size in schizophrenia for hippocampal subfields that mediate cortical-hippocampal interactions. American Journal of Psychiatry. 152:1995;738-748.
7. Benes F.M. Development of the glutamate, GABA and dopamine systems in relation to NRH-induced neurotoxicity. Biological Psychiatry. 38:1995;783-787.
8. A receptor binding in the hippocampal formation of schizophrenic brain. Synapse. 22:1996;338-349.
9. Benes F.M., McSparren J., Bird E.D., Vincent S.L., SanGiovanni J.P. Deficits in small interneurons in prefrontal and anterior cingulate cortex of schizophrenic and schizoaffective patients. Archives of General Psychiatry. 48:1991;996-1001.
10. Benes F.M., Vincent S.L., Alsterberg G., Bird E.D., SanGiovanni J.P. Increased GABA-A receptor binding in superficial layers of cingulate cortex in schizophrenics. Journal of Neuroscience. 112:1992;924-929.
11. Bogerts B. Neuropathology and structural brain imaging in schizophrenia. Current Opinions in Psychiatry. 8:1995;29-33.
12. Bogerts B., Meertz E., Schonfeldt-Bausch R. Basal ganglia and limbic system pathology in schizophrenia. A morphometric study of brain volume and shrinkage. Archives of General Psychiatry. 42:1985;784-791.
13. Bonnano G., Pittaluga A., Fedele E., Raiteri M. Glutamic acid and γ-aminobutyric acid modulate each other's release through heterocarriers sited on the axon terminals of rat brain cortex and hippocampus. Journal of Neurochemistry. 61:1993;222-230.
14. Breier A., Buchanan R.W., Elkashef A., Munson R.C., Kirkpatrick B., Gellad F. Brain morphology and schizophrenia: a magnetic resonance imaging study of limbic, prefrontal cortex and caudate structures. Archives of General Psychiatry. 49:1992;921-926.
15. Brown R., Colter N., Corsellis J.A.N., Crow T.J., Frith C.D., Jagoe J.R., Johnstone E.C., Marsh C. Post-mortem evidence of structural brain changes in schizophrenia: differences in brain weight, temporal horn area and parahippocampal gyrus compared with affective disorder. Archives of General Psychiatry. 43:1986;36-42.
16. Brunello N., Masotto C., Steardo L., Markstein R., Racagni G. New insights into the biology of schizophrenia through the mechanism of action of clozapine. Neuropsychopharmacology. 13:1995;177-213.
17. Buchsbaum M.S. The frontal lobes, basal ganglia and temporal lobes as sites for schizophrenia. Schizophrenia Bulletin. 16:1990;379-389.
18. Buchsbaum M.S., Someya T., Teng C.Y., Abel L., Chin S., Najafi A., Haier R.J., Wu J., Bunney W.E. Jr. PET and MRI of the thalamus in never-medicated patients with schizophrenia. American Journal of Psychiatry. 153:1996;191-199.
19. Bunney W.E. Jr., Hamburg D.A. Methods for reliable longitudinal observation of behavior. Archives of General Psychiatry. 9:1963;280-294.
20. Cameron D.S., Duman R.S., Deutch A.Y. Clozapine induces Fos expression in pyramidal cells and interneurons in the prefrontal cortex in regionally specific manner. Society of Neuroscience Abstracts. 19:1993;1213.
21. Carlsson M., Carlsson A. Interactions between glutamatergic and monoaminergic systems within the basal ganglia - implications for schizophrenia and Parkinson's disease. Trends in Neurosciences. 13:1990;272-276.
22. Chawluk J.B., Alavi A., Dann R., Hurtig H.I., Bais S., Kushner M.J., Zimmerman R.A., Reivich M. Positron emission tomography in aging and dementia: Effect of cerebral atrophy. Journal of Nuclear Medicine. 28:1987;431-437.
23. Chua S.E., McKenna P.J. Schizophrenia - a brain disease? A critical review of structural and functional central abnormality in the disorder. British Journal of Psychiatry. 166:1995;563-582.
24. Cross A.J., Crow T.J., Owen F. γ-Aminobutyric acid in the brain in schizophrenia. Lancet. 1:1979;560-561.
25. Daviss S.R., Lewis D.A. Local circuit neurons of the prefrontal cortex in schizophrenia: selective increase in the density of calbindin-immunoreactive neurons. Psychiatry Research. 59:1995;81-96.
26. Deutch A.Y., Lee M.C., Iadarola M.J. Regionally specific effects of atypical antipsychotic drugs on striatal Fos expression: the nucleus accumbens shell as a locus of antipsychotic action. Molecular and Cellular Neuroscience. 3:1992;332-341.
27. Doran A.R., Boronow J., Weinberger D.R., Wolkowitz O.M., Breier A., Pickar D. Structural brain pathology in schizophrenia revisited. Prefrontal cortex pathology is inversely correlated with cerebrospinal fluid levels of homovanillic acid. Neuropsychopharmacology. 1:1987;25-32.
28. Falkai P., Bogerts B., Rozumek M. Cell loss and volume reduction in the entorhinal cortex of schizophrenics. Biological Psychiatry. 24:1988;515-521.
29. Garbutt J.C., van Kammen D.P. The interaction between GABA and dopamine: implications for schizophrenia. Schizophrenia Bulletin. 9:1983;336-353.
30. Garey L.J., Patel T., Ong W.Y. Loss of dendritic spines from cortical pyramidal cells in schizophrenia. Schizophrenia Research. 11:1994;137.
31. Gerner R.H., Hare T.A. CSF GABA in normal subjects and patients with depression, schizophrenia, mania and anorexia nervosa. American Journal of Psychiatry. 138:1981;1098-1101.
32. Glantz L.A., Lewis D.A. Decreased synaptophysin immunoreactivity in prefrontal cortex of schizophrenics. Biological Psychiatry. 35:1994;717.
33. Goetz K., van Kammen D.P. Computerized axial tomography scans and subtypes of schizophrenia: a review of the literature. Journal of Nervous and Mental Disease. 174:1985;31-41.
34. Gold B.I., Bowers M.B. Jr., Roth R.H., Sweeney D.W. GABA levels on CSF of patients with psychiatric disorders. American Journal of Psychiatry. 136:1980;362-364.
35. Gur R.C., Gur R.E. Hypofrontality in schizophrenia: R.I.P. Lancet. 345:1995;1383-1384.
36. Haber B., Kuriyama K., Roberts E. L-gluctamic acid decarboxylase: a new type in glial cells and human brain gliomas. Science. 168:1970;598-599.
37. 3H] Muscimol binding sites increased in autopsied brains of chronic schizophrenics. Life Sciences. 40:1987;259-266.
38. Javitt D.C., Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. American Journal of Psychiatry. 148:1991;1301-1308.
39. Kety S.S., Woodford R.B., Harmel M.H., Freyhan F.A., Appel K.E., Schmidt C.F. Cerebral blood flow and metabolism in schizophrenia. The effects of barbiturate semi-narcosis, insulin coma and electroshock. American Journal of Psychiatry. 104:1948;765-770.
40. Kim J.S., Kornhuber H.H., Schmid-Burgk W., Holzmuller B. Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neuroscience Letters. 20:1980;379-382.
41. Korpi E.R., Kleinman J.E., Goodman S.I., Wyatt R.J. Neurotransmitter amino acids in post-mortem brains of chronic schizophrenic patients. Psychiatry Research. 22:1987;291-301.
42. Krystal J.H., Karper L.P., Seibyl J.P., Delaney R., Bremner J.D., Bowers M.B., Charney D.S. Dose-related effects of the NDMA antagonist, ketamine, in healthy humans. Schizophrenia Research. 9:1993;240-241.
43. Lahti A.C., LaPorte D.J., Mokriski B., Tamminga C.A. Effects of the NMDA antagonist ketamine in schizophrenic patients. Society of Neuroscience Abstracts. 19:1993;1351.
44. Lewis D.A., Anderson S.A. The functional architecture of the prefrontal cortex and schizophrenia. Psychological Medicine. 25:1995;887-894.
45. Lichtshtein D., Dobkin J., Ebstein R.P., Biederman J., Rimon R., Belmaker R.H. Gamma-aminobutyric acid (GABA) in the CSF of schizophrenic patients: before and after neuroleptic treatment. British Journal of Psychiatry. 132:1978;145-148.
46. Lieberman J., Bogerts B., Degreef G., Ashtari M., Lantos G., Alvir J. Qualitative assessment of brain morphology in acute and chronic schizophrenia. American Journal of Psychiatry. 149:1992;784-794.
47. Lieberman J., Jody D., Alvir J.M.J., Ashtari M., Levi D.L., Bogerts B., Degreef G., Mayerhoff D.I., Cooper T. Brain morphology, dopamine and eye tracking abnormalities in first episode schizophrenia: prevalence and clinical correlates. Archives of General Psychiatry. 50:1993;357-368.
48. Lim K.O., Sullivan E.V., Zipursky R.B., Pfefferbaum A. Cortical gray matter volume deficits in schizophrenia: a replication. Schizophrenia Research. 20:1996;157-164.
49. Manyam N.V.B., Hare T.A. Rapid and sensitive ion-exchange fluorometric measurement of γ-aminobutyric acid in physiological fluids. Analytical Biochemistry. 101:1980;349-355.
50. 2 receptors in the rat brain. Neuroscience. 54:1993;701-717.
51. Olney J.W., Farber N.B. Glutamate receptor dysfunction in schizophrenia. Archives of General Psychiatry. 52:1995;998-1007.
52. Pakkenberg B. Total nerve cell number in neocortex in chronic schizophrenics and controls estimated using optical disectors. Biological Psychiatry. 34:1993;768-772.
53. Penny J.B., Young A.B. Striatal inhomogeneities and basal ganglia function. Movement Disorders. 1:1986;3-15.
54. Perry T.L., Hansen S., Jones K. Schizophrenia, tardive dyskinesia and brain GABA. Biological Psychiatry. 25:1989;200-206.
55. Perry T.L., Kish S.J., Buchanan J., Hansen S. γ-Aminobutyric-acid deficiency in brains of schizophrenic patients. Lancet. 1:1979;237-239.
56. Petty F., Kramer G.L., Fulton M., Moeller F.G., Rush A.J. Low plasma GABA is a trait-like marker for bipolar illness. Neuropsychopharmacology. 9:1993;125-132.
57. Petty F., Sherman A.D. Plasma GABA levels in psychiatric illness. Journal of Affective Disorders. 6:1984;131-138.
58. Raz S., Raz N. Structural brain abnormalities in the major psychoses: a quantitative review of the evidence from computerized imaging. Psychological Bulletin. 108:1990;93-108.
59. Reynolds G.P., Czudek C., Andrews H.B. Deficit and hemispheric asymmetry of GABA uptake sites in the hippocampus in schizophrenia. Biological Psychiatry. 27:1990;1038-1044.
60. Rieder R.O., Donnelly E.F., Heardt J.R., Waldman I.N. Sulcal prominence in young chronic schizophrenic patients: CT scan findings associated with impairment on neuropsychological tests. Psychiatry Research. 1:1979;1-8.
61. Rieder R.O., Mann L.S., Weinberger D.R., van Kammen D.P., Post R.M. Computed tomographic scans in patients with schizophrenia, schizoaffective and bipolar affective disorders. Archives of General Psychiatry. 40:1983;735-739.
62. Roberts E. A hypothesis suggesting that there is a defect in the GABA system in schizophrenia. Neuroscience Research Bulletin. 10:1972;482-496.
63. Robertson G.S., Fibiger H.C. Neuroleptics increase c-fos expression in the forebrain: contrasting effects of haloperidol and clozapine. Neuroscience. 46:1992;315-328.
64. Rossi A., Stratto P., Mancici F., Gallucci M., Mattei P., Core L., diMichele V., Casacchia M. Magnetic resonance imaging findings of amygdala-anterior hippocampus shrinkage in male patients with schizophrenia. Psychiatry Research. 52:1994;43-53.
65. Schafer D.F., Jones E.A. Hepatic encephalopathy and the γ-aminobutryic acid neurotransmitter system. Lancet. 1(8262):1982;18-20.
66. Selemon L.D., Rajkowska G., Goldman-Rakic P.S. Abnormally high neuronal density in the schizophrenic cortex: a morphometric analysis of prefrontal area 9 and occipital area 17. Archives of General Psychiatry. 52:1995;805-818.
67. 2 receptors in interneurons. Synapse. 9:1991;208-218.
68. Shelton, R.C., Weinberger, D.R., 1986. X-ray computerized tomography studies in schizophrenia: a review and synthesis. In: Nasrallah, H.A., Weinberger, D.R. (Eds.), The Neurology of Schizophrenia. Elsevier, New York, pp. 207-250.
69. Sherman A.D., Davidson A.T., Baruah S., Hedgewood T.S., Waziri R. Evidence of glutamatergic deficiency in schizophrenia. Neuroscience Letters. 121:1991;77-80.
70. Simpson M.D.C., Slater P., Deakin J.F.W., Royston M.C., Skan W.J. Reduced GABA uptake sites in the temporal lobe in schizophrenia. Neuroscience Letters. 107:1989;211-215.
71. Simpson M.D.C., Slater P., Royston M.C., Deakin J.F.W. Regionally selective deficits in uptake sites for glutamate and gamma-aminobutyric acid in the basal ganglia in schizophrenia. Psychiatry Research. 42:1992;273-282.
72. Spokes E.G.S., Garrett N.J., Rossor M.N., Iversen L.L. Distribution of GABA in post-mortem brain tissue from control, psychotic and Huntington's chorea subjects. Journal of the Neurological Sciences. 48:1980;303-313.
73. Squires R.F., Saederup E. A review of evidence for GABAergic predominance/glutamatergic deficit as a common etiological factor in both schizophrenia and affective psychoses: more support for a continuum hypothesis of 'functional'. Neurochemical Research. 16:1991;1099-1111.
74. Stanley J.A., Williamson P.C., Drost D.J., Carr T.J., Rylett J., Malla A., Thompson R.T. An in vivo study of the prefrontal cortex of schizophrenic patients at different stages of illness via phosphorus magnetic resonance spectroscopy. Archives of General Psychiatry. 52:1995;399-406.
75. Suddath R.L., Christison G.W., Torrey E.F., Casanova M.F., Weinberger D.R. Anatomical abnormalities in the brain of monozygotic twins discordant for schizophrenia. New England Journal of Medicine. 322:1990;789-794.
76. Svensson A., Carlsson M.L., Carlsson A. Interaction between glutamatergic and dopaminergic tone in the nucleus accumbens of mice: evidence for a dual glutamatergic function with respect to psychomotor control. Journal of Neural Transmission (General section). 88:1992;235-240.
77. Toru M., Watanabe S., Shibuya H., Nishikawa T., Noda K., Mitsushio H., Ichikawa H., Kurumaji A., Takashima M., Mataga N., Ogawa A. Neurotransmitters, receptors and neuropeptides in post-mortem brains of chronic schizophrenic patients. Acta Psychiatrica Scandinavica. 78:1988;121-137.
78. Tsai, G., van Kammen, D.P., Chen, S., Kelley, M.E., Coyle, J.T. (submitted). Glutamatergic neurotransmission involves structural and clinical deficits of schizophrenia.
79. van Kammen D.P. γ-Aminobutyric acid (GABA) and the dopamine hypothesis of schizophrenia. American Journal of Psychiatry. 134:1977;463-464.
80. van Kammen, D.P., Sternberg, D.E., 1980. CSF studies in schizophrenia. In: Wood, J.H. (Ed.), Neurobiology of Cerbrospinal Fluid, vol I. Plenum Press, New York, pp. 719-742.
81. van Kammen D.P., Mann L.S., Sternberg D.E., Scheinin M., van Kammen W.B., Ninan P.T., Marder S.R., Rieder R.O., Linnoila M. Dopamine-β-hydroxylase activity and homovanillic acid in spinal fluid of schizophrenic patients with brian atrophy. Science. 220:1983;974-977.
82. van Kammen D.P., Sternberg D.E., Hare T.A., Waters R.N., Bunney W.E. Jr. CSF γ-aminobutyric acid in schizophrenia: low values in recently ill patients. Archives of General Psychiatry. 39:1982;91-97.
83. Weinberger D.R., Lipska B.K. Cortical maldevelopment, anti-psychotic drugs and schizophrenia: a search for common ground. Schizophrenia Research. 16:1995;87-110.
84. Woo T.-U., Miller J.L., Lewis D.A. Schizophrenia and the parvalbumin-containing class of cortical local circuit neurons. American Journal of Psychiatry. 154:1997;1013-1015.
85. Zachman M., Tocci P., Nyhan W.L. The occurrence of γ-aminobutyric acid in human tissues other than brain. Journal of Biological Chemistry. 241:1966;1355-1358.
86. Zipursky R.B., Lim K.O., Sullivan E.V., Brown B.W., Pfefferbaum A. Widespread cerebral gray matter volume deficits in schizophrenia. Archives of General Psychiatry. 49:1992;195-205.